Literature DB >> 11239902

Noradrenergic dysfunction in the prefrontal cortex in depression: an [15O] H2O PET study of the neuromodulatory effects of clonidine.

C H Fu1, L J Reed, J H Meyer, S Kennedy, S Houle, B S Eisfeld, G M Brown.   

Abstract

BACKGROUND: Noradrenergic dysfunction has been consistently implicated in depression. Much of the evidence, though, has been indirect, such as an attenuated growth hormone response to the alpha2-adrenoceptor agonist clonidine. To more directly examine central functioning of the noradrenergic system in depression, we have used [15O] H2O positron emission tomography (PET) to measure cerebral blood flow (rCBF) in combination with clonidine as a neuromodulatory probe.
METHODS: Subjects were six depressed and six healthy women, medication free and matched for age and phase of menstrual cycle. Two PET scans were acquired at baseline and two scans at 20 and 35 min following an intravenous clonidine infusion of 1.4 microg/kg while subjects performed a sustained attention task.
RESULTS: The growth hormone response did not show a significant difference between groups. However, PET results revealed a difference in the right superior prefrontal cortex that was resolved as an interaction from decreased rCBF in healthy control subjects but increased rCBF in the depressed group, which was not accounted for by differences in task performance.
CONCLUSIONS: This differential effect of clonidine in the right prefrontal cortex provides in vivo evidence of noradrenergic dysfunction in depression, which we postulate arises from functionally impaired presynaptic alpha2-adrenoceptors as well as regionally "supersensitive" postsynaptic cortical alpha2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239902     DOI: 10.1016/s0006-3223(00)01050-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  α₂-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims.

Authors:  Elsa M Valdizán; Rebeca Díez-Alarcia; Javier González-Maeso; Fuencisla Pilar-Cuéllar; Jesús A García-Sevilla; J Javier Meana; Angel Pazos
Journal:  Biol Psychiatry       Date:  2010-09-22       Impact factor: 13.382

2.  Differential modulation of α-1 adrenoceptor subtypes by antidepressants in the rat brain.

Authors:  D Ramakrishna; M N Subhash
Journal:  J Neural Transm (Vienna)       Date:  2010-12-07       Impact factor: 3.575

3.  Platelet imidazoline receptors as state marker of depressive symptomatology.

Authors:  John Piletz; Robert Baker; Angelos Halaris
Journal:  J Psychiatr Res       Date:  2006-12-12       Impact factor: 4.791

Review 4.  The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research.

Authors:  Patrick E McKnight; Todd B Kashdan
Journal:  Clin Psychol Rev       Date:  2009-02-07

5.  Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine.

Authors:  Cynthia H Y Fu; Sergi G Costafreda; Anjali Sankar; Tracey M Adams; Mark M Rasenick; Peng Liu; Robert Donati; Luigi A Maglanoc; Paul Horton; Lauren B Marangell
Journal:  BMC Psychiatry       Date:  2015-04-14       Impact factor: 3.630

Review 6.  Widespread Morphometric Abnormalities in Major Depression: Neuroplasticity and Potential for Biomarker Development.

Authors:  Cynthia H Y Fu; Yong Fan; Christos Davatzikos
Journal:  Neuroimaging Clin N Am       Date:  2019-11-08       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.